Drug intelligence / Profile preview

AKBM-3031

Development stage: Unknown
Lead developer: Aker BioMarine
Modality: Small Molecules
Administration: Oral

Overview

AKBM-3031 is a krill-derived phospholipid concentrate developed by Aker BioMarine in collaboration with the Lupus Research Alliance. It is specifically investigated for the treatment of systemic lupus erythematosus (SLE) to address the omega-3 fatty acid deficiency associated with the condition. Unlike traditional fish oil, AKBM-3031 provides eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a phospholipid form, which is hypothesized to improve cellular uptake and integration into cell membranes, thereby modulating inflammatory responses. The product was evaluated in a Phase 2 clinical trial (NCT03626311) to assess its efficacy in reducing disease activity in SLE patients.

Brand names: Superba KrillSuperba 2Superba2Superba-2Superba Boost
Other names: Krill OilKrill Phospholipids Concentrate

Beyond the preview

Go deeper on AKBM-3031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKBM-3031.

Explore the full profile